𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Quality of life assessment. An independent prognostic variable for survival in lung cancer

✍ Scribed by Patricia A. Ganz; J. Jack Lee; Jessie Siau

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
441 KB
Volume
67
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Plasminogen activator inhibitor-1 is an
Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients
✍ Setsuko K. Chambers; Christina M. Ivins; Maria L. Carcangiu πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 French βš– 103 KB πŸ‘ 2 views

High levels of plasminogen activator inhibitor-1 (PAI-1) in tissue extracts have been associated with poor prognosis in many epithelial cancers. Ovarian cancers contain a higher concentration of PAI-1 than benign ovarian tumors or normal ovaries. Reports, however, on the prognostic value of PAI-1 co

Defining an international research agend
Defining an international research agenda for quality of life in men with prostate cancer
✍ Litwin, Mark S.; Fitzpatrick, John M.; Fossa, Sophie D.; Newling, Don W.W. πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 168 KB πŸ‘ 2 views

## BACKGROUND. While the traditional goal in the management of patients with prostate cancer has been to maximize survival, the recent advent of the medical outcomes movement has underscored the importance of patient-centered issues, such as health-related quality of life (HRQOL). METHODS. In this

Practical issues in quality of life asse
Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Cancer Research
✍ JΓΌrg Bernhard; Heidi Gusset; Christoph HΓΌrny πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 130 KB πŸ‘ 2 views

Quality of life (QOL) assessment has become an integrated part in some advanced disease trials and to a lesser extent in early disease trials conducted by the Swiss Group for Clinical Cancer Research (SAKK). In general, the concept of QOL endpoints and the additional work of collecting these data is